Sanofi, Regeneron etch out another PhIII victory for Dupixent, easing severe itch and clearing lesions
Sanofi and Regeneron can boast of another inflammatory disease where Dupixent has proven effective.
The best-selling drug, which targets both IL-4 and IL-13, has delivered …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
